$162.18 +0.60 (%) Amgen Inc - NASDAQ

Oct. 31, 2014 | 04:00 PM

Partner Headlines

  1. AbbVie Beats Q3 Earnings Estimates, Raises Guidance

    IBD | Oct. 31, 2014 | 14:25PM EST
  2. Ebola Vaccine Contenders

    Benzinga | Oct. 30, 2014 | 10:44AM EST
  3. Stocks Trim Losses After Fed Report; Solarwinds Soars

    IBD | Oct. 29, 2014 | 16:22PM EST
  4. UPDATE: Nomura Upgrades Amgen

    Benzinga | Oct. 29, 2014 | 11:42AM EST
  5. Amgen resists pressure to split

    IBD | Oct. 28, 2014 | 18:43PM EST
  6. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus | Oct. 28, 2014 | 15:34PM EST
  7. Amgen Refuses To Split, But Plans Hearten Investors

    IBD | Oct. 28, 2014 | 14:18PM EST
  8. Amgen At All-Time High, Deutsche Bank Ups Price Target

    Benzinga | Oct. 28, 2014 | 13:33PM EST
  9. Stocks Extend Gains As Alibaba, Tesla Rally

    IBD | Oct. 28, 2014 | 12:04PM EST
  10. Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing

    IBD | Oct. 28, 2014 | 10:36AM EST
  11. Amgen Rallies 3% After Announcing Growth And Capital Plans

    Benzinga | Oct. 28, 2014 | 09:32AM EST
  12. Four Biotechs Lead Health Care Stocks In Big Cap 20

    IBD | Oct. 27, 2014 | 19:00PM EST
  13. Amgen Q3 Earnings Beat Estimates; Guidance Mixed

    IBD | Oct. 27, 2014 | 18:56PM EST
  14. Amgen Earnings Clear Views

    IBD | Oct. 27, 2014 | 18:49PM EST
  15. Amgen Beats Q3 Earnings Estimates

    Benzinga | Oct. 27, 2014 | 17:16PM EST
  16. Twitter Off, Amgen, Buffalo Wild Wings Up After Hours

    IBD | Oct. 27, 2014 | 17:04PM EST
  17. Dow, Nasdaq Battle Near Flat Line; Energy Weighs On S&P 500

    IBD | Oct. 27, 2014 | 15:00PM EST
  18. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations

    Benzinga | Oct. 27, 2014 | 08:19AM EST
  19. Earnings Scheduled For October 27, 2014

    Benzinga | Oct. 27, 2014 | 05:06AM EST
  20. Keep an Eye on These 7 Stocks for October 27, 2014

    Benzinga | Oct. 27, 2014 | 04:21AM EST
  21. Stocks Put End To Four-Week Slide

    IBD | Oct. 24, 2014 | 16:56PM EST
  22. Fast Money Picks For October 23

    Benzinga | Oct. 23, 2014 | 07:00AM EST
  23. Drug ETFs Attractive Buys On Pullback

    Benzinga | Oct. 22, 2014 | 17:10PM EST
  24. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD | Oct. 22, 2014 | 17:01PM EST
  25. Daniel Loeb Comments on Amgen Inc

    GuruFocus | Oct. 22, 2014 | 12:06PM EST
  26. Third Point Q3 2014 Investor Letter

    GuruFocus | Oct. 22, 2014 | 10:24AM EST
  27. Markets In Rally Mode: S&P 500 And Nasdaq Surge As Dow Lags

    Benzinga | Oct. 21, 2014 | 16:41PM EST
  28. Third Point's Notable Additions And Exit: Alibaba, eBay, Sony

    Benzinga | Oct. 21, 2014 | 15:38PM EST
  29. Stocks To Watch For October 20, 2014

    Benzinga | Oct. 20, 2014 | 04:43AM EST
  30. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD | Oct. 18, 2014 | 08:02AM EST
  31. Regeneron's Eylea Tops Rivals

    IBD | Oct. 17, 2014 | 18:45PM EST
  32. Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors

    Benzinga | Oct. 17, 2014 | 16:20PM EST
  33. Regeneron Eye Drug Beats Rivals While Amgen Sues

    IBD | Oct. 17, 2014 | 11:27AM EST
  34. Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

    Benzinga | Oct. 17, 2014 | 09:01AM EST
  35. Most Top Industry Groups Fall Harder Than Market

    IBD | Oct. 10, 2014 | 17:58PM EST
  36. UPDATE: Amgen's BiTE Received FDA Priority Review Designation

    Benzinga | Oct. 9, 2014 | 16:06PM EST
  37. Illumina Pads Gene Sequencing Lead With Pharma Deals

    IBD | Oct. 8, 2014 | 16:04PM EST
  38. Some Old Stocks Still Have Young Legs

    IBD | Oct. 6, 2014 | 18:47PM EST
  39. Amgen, Inc. Showing Strong Performance Despite Low Beta

    Benzinga | Sep. 30, 2014 | 12:06PM EST
  40. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD | Sep. 24, 2014 | 13:27PM EST
  41. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD | Sep. 22, 2014 | 19:05PM EST
  42. These 3 Biotech Stocks Just Hit New Highs

    Benzinga | Sep. 22, 2014 | 13:31PM EST
  43. Amgen Submits Biologics License Application For Investigational BiTE Immunotherapy Blinatumomab

    Benzinga | Sep. 22, 2014 | 09:02AM EST
  44. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus | Sep. 22, 2014 | 03:12AM EST
  45. Insider Buys at Halozyme Look to Improve Stock Outlook

    GuruFocus | Sep. 18, 2014 | 17:49PM EST
  46. Amgen, Inc. Poised To Break Higher

    Benzinga | Sep. 17, 2014 | 14:34PM EST
  47. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab Doesn't Need To Be Forgotten

    Benzinga | Sep. 17, 2014 | 09:50AM EST
  48. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare Conference

    Benzinga | Sep. 11, 2014 | 08:54AM EST
  49. Amgen, Inc. Showing More Upside Potential

    Benzinga | Sep. 10, 2014 | 16:06PM EST
  50. Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

    Benzinga | Sep. 5, 2014 | 09:27AM EST
Trading Center